Genprex Inc (GNPX) Stock Price, Quote & News

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 774 4679

Website: www.genprex.com

Address:

3300 Bee Cave Road, Suite 650-227, Austin, United States

StockHounding Oct. 25 at 4:42 PM

$EEIQ trading like a company that actually reads its own filings. You can see a slow, deliberate walk-up on the daily — not hype candles, just steady bid pressure. The Form 6-K filed Aug 26 2025 (Item 2 – Operational Update) notes “continued expansion of academic programs and careful allocation of working capital.” That’s management talk for “we’re growing, but we’re not burning cash.” The chart agrees: no panic, just pacing. $DUOT building a quiet base $HCDI curling off the bottom $GNPX testing prior resistance $OPTX range tightening nicely

0 · Reply

YGLD Oct. 25 at 2:59 PM

No Wonder Everyone’s Angry $BYND $DJI $GNPX $GNTA $SPY

1 · Reply

MedicineMan777 Oct. 25 at 2:14 PM

$GNPX POSTER SESSION C 12:30-4 p.m. | Level 2, Exhibit Hall D it is not specifically identified in the program what the session contains but that is Reqorsa.

0 · Reply

YGLD Oct. 25 at 1:41 PM

Thinking You Can Do It 24/7 Was The Facade Sold To Newcomers For Decades ⚠️ The Journey Doesn’t Start Until You Realize This Is Something Done A Few Times A Month So If You’ve Been At It A Decade and Still Think You Can Trade Daily You’re Still A Beginner - Literally You Haven’t Grown A Bit $BYND $GNPX $GNTA $SPY $DJI

1 · Reply

Jsubsierra Oct. 25 at 10:31 AM

$GNPX En el programa de la presentación no mencionan ni a GNPX ni a Reqorsa

2 · Reply

Nelsons93 Oct. 25 at 9:54 AM

$GNPX Setup looks smarter than people think 🔥 The reverse split and small offering before the AACR presentation were actually well timed. They cleared compliance without tanking the stock. Just enough to reset and give the company room to move. Now all eyes are on today’s data at AACR-NCI-EORTC (Poster Session C) — focused on TUSC2 (REQORSA) in ALK-positive cancers. If the results hit, it’s not just validation… it’s expansion. That’s new market potential and a major credibility boost. Feels like they’ve positioned this perfectly, cleaned up the balance, tightened the float, and now bringing the science front and centre. Could be the start of a real turnaround. #GNPX #REQORSA #GeneTherapy #AACR2025 https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2025/program-saturday-october-25/

1 · Reply

crabhunter Oct. 25 at 5:01 AM

$GNPX So a bulls thesis on such a small ($8M) offering is this… Management did not want to issue too many shares at this time/price. So they did enough to satisfy compliance and get through eoy. Because they have news or developments that will increase the price of the stock. And AFTER that is made known AND the stock is valued appropriately they will go to the market for more money. They didn’t screw investors. Had they wanted to, the offering could have been done at much lower prices.

0 · Reply

crabhunter Oct. 25 at 1:40 AM

$GNPX https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2025/program-saturday-october-25/

0 · Reply

MedicineMan777 Oct. 25 at 1:36 AM

$GNPX I think the RS and Offering before the presentation is genius because many people are still holding for the presentation. Also you want to do it when you are far from the 1$ price and they did it as small as possible to have the smallest impact.

0 · Reply

crabhunter Oct. 25 at 1:33 AM

$GNPX Never mind https://www.genprex.com/2025/10/23/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-ta-2/

0 · Reply

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 7:00 AM EDT - 2 days ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 2, 2025, 8:30 AM EDT - 7 weeks ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Aug 18, 2025, 9:29 AM EDT - 2 months ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 4, 2025, 8:30 AM EDT - 2 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Jun 24, 2025, 9:25 AM EDT - 4 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 4 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 3, 2025, 7:00 AM EDT - 5 months ago

Genprex to Participate at BIO 2025 International Convention

May 29, 2025, 7:00 AM EDT - 5 months ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 28, 2025, 7:00 AM EDT - 5 months ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 7, 2025, 7:00 AM EDT - 6 months ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 6, 2025, 7:00 AM EDT - 6 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Apr 30, 2025, 7:30 AM EDT - 6 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 6 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 28, 2025, 7:30 AM EDT - 6 months ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 24, 2025, 8:15 AM EDT - 6 months ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 22, 2025, 8:15 AM EDT - 6 months ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Mar 26, 2025, 8:15 AM EDT - 7 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 25, 2025, 8:15 AM EDT - 7 months ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 4, 2025, 8:15 AM EST - 8 months ago

Genprex to Participate at BIO Europe Spring 2025

Feb 19, 2025, 8:15 AM EST - 8 months ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 18, 2025, 8:15 AM EST - 8 months ago

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 13, 2025, 8:15 AM EST - 9 months ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 9 months ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 6, 2025, 9:15 AM EST - 10 months ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 9:15 AM EST - 11 months ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 5, 2024, 9:29 AM EST - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 10, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 7, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Sep 23, 2024, 9:29 AM EDT - 1 year ago

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Sep 19, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Sep 4, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Aug 15, 2024, 9:30 AM EDT - 1 year ago

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Aug 14, 2024, 9:25 AM EDT - 1 year ago

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Aug 13, 2024, 8:31 AM EDT - 1 year ago

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Genprex to Present at the August Sidoti Microcap Conference

Jun 27, 2024, 8:31 AM EDT - 1 year ago

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

May 30, 2024, 8:31 AM EDT - 1 year ago

Genprex to Present at the 2024 BIO International Convention

May 14, 2024, 8:31 AM EDT - 1 year ago

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

May 13, 2024, 8:31 AM EDT - 1 year ago

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

May 8, 2024, 6:08 PM EDT - 1 year ago

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

May 1, 2024, 8:31 AM EDT - 1 year ago

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

Apr 9, 2024, 8:31 AM EDT - 1 year ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Apr 3, 2024, 8:31 AM EDT - 1 year ago

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Apr 2, 2024, 8:31 AM EDT - 1 year ago

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

StockHounding Oct. 25 at 4:42 PM

0 · Reply

YGLD Oct. 25 at 2:59 PM

No Wonder Everyone’s Angry $BYND $DJI $GNPX $GNTA $SPY

1 · Reply

MedicineMan777 Oct. 25 at 2:14 PM

$GNPX POSTER SESSION C 12:30-4 p.m. | Level 2, Exhibit Hall D it is not specifically identified in the program what the session contains but that is Reqorsa.

0 · Reply

YGLD Oct. 25 at 1:41 PM

1 · Reply

Jsubsierra Oct. 25 at 10:31 AM

$GNPX En el programa de la presentación no mencionan ni a GNPX ni a Reqorsa

2 · Reply

Nelsons93 Oct. 25 at 9:54 AM

1 · Reply

crabhunter Oct. 25 at 5:01 AM

0 · Reply

crabhunter Oct. 25 at 1:40 AM

$GNPX https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2025/program-saturday-october-25/

0 · Reply

MedicineMan777 Oct. 25 at 1:36 AM

0 · Reply

crabhunter Oct. 25 at 1:33 AM

0 · Reply

crabhunter Oct. 25 at 1:23 AM

$GNPX Anyone have a link for the conference?

0 · Reply